Edition:
India

Corbus Pharmaceuticals Holdings Inc (CRBP.OQ)

CRBP.OQ on NASDAQ Stock Exchange Global Market

6.65USD
1:30am IST
Change (% chg)

$-0.10 (-1.48%)
Prev Close
$6.75
Open
$6.70
Day's High
$6.80
Day's Low
$6.65
Volume
57,572
Avg. Vol
162,517
52-wk High
$9.85
52-wk Low
$5.35

Chart for

About

Corbus Pharmaceuticals Holdings, Inc. is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat rare, chronic and serious inflammatory and fibrotic diseases. The Company operates through developing and commercializing therapeutics to treat rare life-threa... (more)

Overall

Beta: --
Market Cap(Mil.): $371.63
Shares Outstanding(Mil.): 50.22
Dividend: --
Yield (%): --

Financials

BRIEF-Corbus Pharmaceuticals Reports 2017 Financial Results And Provides Clinical Update

* CORBUS PHARMACEUTICALS REPORTS 2017 FINANCIAL RESULTS AND PROVIDES CLINICAL UPDATE

12 Mar 2018

BRIEF-Corbus Pharmaceuticals Receives $25 Mln Development Award From The Cystic Fibrosis Foundation

* CORBUS PHARMACEUTICALS RECEIVES $25 MILLION DEVELOPMENT AWARD FROM THE CYSTIC FIBROSIS FOUNDATION TO SUPPORT PHASE 2B CLINICAL STUDY OF LENABASUM Source text for Eikon: Further company coverage:

30 Jan 2018

BRIEF-Corbus Agrees With FDA On Phase 2B Cystic Fibrosis Study Design With Pulmonary Exacerbations As Sole Primary Endpoint

* CORBUS PHARMACEUTICALS ANNOUNCES AGREEMENT WITH FDA ON PHASE 2B CYSTIC FIBROSIS STUDY DESIGN WITH PULMONARY EXACERBATIONS AS SOLE PRIMARY ENDPOINT

30 Jan 2018

Corbus cystic fibrosis drug to get FDA review on flare-up data

Corbus Pharmaceuticals Holdings Inc said on Monday the U.S. Food and Drug Administration will evaluate its experimental cystic fibrosis drug without requiring proof the product improves lung function, dramatically cutting the time and cost it will take Corbus to develop the drug.

30 Jan 2018

Corbus cystic fibrosis drug to get U.S. FDA review on flare-up data

Jan 29 Corbus Pharmaceuticals Holdings Inc said on Monday the U.S. Food and Drug Administration will evaluate its experimental cystic fibrosis drug without requiring proof the product improves lung function, dramatically cutting the time and cost it will take Corbus to develop the drug.

30 Jan 2018

BRIEF-Corbus Pharmaceuticals Files For Mixed Shelf Of Up To $200 Mln ‍​

* CORBUS PHARMACEUTICALS HOLDINGS INC FILES FOR MIXED SHELF OF UP TO $200 MILLION - SEC FILING ‍​ Source text: (http://bit.ly/2EciBBu) Further company coverage:

06 Jan 2018

BRIEF-Corbus Pharma Initiates Phase 2 Study Of Anabasum For Treatment Of Systemic Lupus Erythematosus

* CORBUS PHARMACEUTICALS ANNOUNCES INITIATION OF PHASE 2 STUDY OF ANABASUM FOR TREATMENT OF SYSTEMIC LUPUS ERYTHEMATOSUS Source text for Eikon: Further company coverage:

22 Dec 2017

BRIEF-Corbus Pharmaceuticals Q3 loss per share $0.14

* Corbus Pharmaceuticals reports 2017 third quarter financial results and highlights recent corporate and clinical advancements

08 Nov 2017

BRIEF-Corbus Pharma reports improvement in skin conditions in a mid-stage study

* Corbus Pharmaceuticals reports significant improvement in mRSS and other clinical outcomes at 28-weeks in systemic sclerosis open-label extension of phase 2 study

06 Nov 2017

BRIEF-Corbus Pharma prices underwritten public offering of common stock

* Corbus Pharmaceuticals Holdings, Inc. prices underwritten public offering of common stock

24 Oct 2017

Competitors

Earnings vs. Estimates